Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Inclusion Criteria: * Must be able to provide informed consent * In Dose-Escalation: Must have solid tumor malignancy or cutaneous T-cell lymphoma that has relapsed and is refractory to standard therapy, or for which no standard therapy exists * In Expansion Phase: Must have melanoma or ovarian cancer that is histologically or cytologically confirmed * Ovarian cancer patients must have recurrent of persistent non-mucinous disease, and must not have received more than 2 prior chemotherapeutic regimens * Melanoma patients must have recurrent or persistent non-ocular AJCC Stage IIIC or IV disease that is surgically incurable and unresectable * Melanoma patients with documented BRAF mutation that is known to be responsive to BRAF inhibitors must have failed or be intolerant to such inhibitors * Must have measurable disease * Must be able to provide access to archival (Dose-Escalation Phase) and/or fresh tumor tissue (Dose-Escalation and Expansion Phases) at Screening prior to study entry * Must by at least 18 years old * Must have adequate organ function Exclusion Criteria: * Prior cancer therapies must have completed at least 14 days or 5 half-lives (whichever is longer) prior to first dose of AMP-224 * Prior treatment with an anti-PD1 antibody therapy * Known antibody response against prior antibody therapy or fusion protein therapeutics * Major surgery within 4 weeks prior to first dose of AMP-224 * Prior allogeneic or autologous bone marrow or organ transplantation * Known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism * Received an immunomodulatory drug within 2 weeks of first dose of AMP-224 * Active infections requiring antibiotics, physician monitoring, or recurrent fevers \>100.4 degrees fahrenheit associated with a clinical diagnosis of active infection * Patients with cirrhosis * Clinically significant cardiac or electrocardiogram abnormalities * History or evidence of HIV * Active viral disease (except when the viral infection is associated with the malignancy) * Regular use of illicit drugs or a recent history of substance abuse * Pregnant or breastfeeding women